Holen Sie sich die Stockscreener-App
22.24
4.55%
-1.06
Handel nachbörslich:
22.70
0.46
+2.07%
Kailera Therapeutics Inc Aktie (KLRA) Neueste Nachrichten
Eli Lilly's Market Cap Balloons, Again, On This IPO's Setback - Investor's Business Daily
Kailera falls after late-stage trial data for oral GLP-1 candidate - Seeking Alpha
Kailera shares tumble on high nausea rates despite weight-loss drug's success - Reuters
Kailera reports 11.1% weight loss data - grafa.com
Kailera Therapeutics Announces Positive Topline Data From Two Hengrui Pharma Phase 3 Clinical Trials Of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535 - marketscreener.com
Kailera’s obesity drug meets main goal of late-stage trials in China - 101 WIXX
Kailera says obesity pill succeeds in late-stage trial in China - Yahoo Finance
Kailera’s weight-loss drug meets main goal of late-stage trials in China - hi99.com
Kailera's weight-loss drug meets main goal of late-stage trials in China - marketscreener.com
Kailera’s GLP-1 drug meets main goal of late-stage trials - WTVB
Kailera's GLP-1 drug meets main goal of late-stage trials - Yahoo Finance
Kailera Therapeutics Announces Positive Topline Data from - GlobeNewswire
KLRA Price Today: Kailera Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Kailera Therapeutics (KLRA) Stock Looks Overvalued Despite Its 20% Slump - Yahoo Finance
Top Kailera Therapeutics (KLRA) Competitors 2026 - MarketBeat
Kailera appoints Kathleen Tregoning as chief corporate affairs officer - The Pharma Letter
Kailera Therapeutics, Inc.(NasdaqGS: KLRA) added to Russell 2000 Index - marketscreener.com
Kailera Therapeutics, Inc.(NasdaqGS: KLRA) added to Russell 2000 Value Benchmark - marketscreener.com
Kailera Appoints New Chief Corporate Affairs Officer - Intellectia AI
Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer - The Manila Times
Kailera Therapeutics, Inc.(NasdaqGS: KLRA) added to Russell 2000 Growth Benchmark - marketscreener.com
Press Release: Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer - Moomoo
Kailera Therapeutics, Inc.(NasdaqGS: KLRA) added to Russell 3000E Value Benchmark - marketscreener.com
Kailera Therapeutics, Inc. (KLRA) Total Assets (Quarterly) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Gross Margin (TTM) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Net Income (TTM) - Zacks Investment Research
Enterprise value to revenue forward of Kailera Therapeutics, Inc. – NASDAQ:KLRA - TradingView
Kailera Therapeutics, Inc. (KLRA) Return On Assets (TTM) - Zacks Investment Research
Price to sales forward of Kailera Therapeutics, Inc. – NASDAQ:KLRA - TradingView
Kailera Therapeutics, Inc. (KLRA) Price Book Value - Zacks Investment Research
Price to book forward of Kailera Therapeutics, Inc. – NASDAQ:KLRA - TradingView
Kailera Therapeutics (KLRA) Insider Trading Activity 2026 $KLRA - MarketBeat
Price to earnings forward of Kailera Therapeutics, Inc. – NASDAQ:KLRA - TradingView
Kailera Therapeutics, Inc.(NasdaqGS: KLRA) added to S&P TMI Index - marketscreener.com
Latest KLRA ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
KLRA Technical Analysis & ETF Price Forecast - Intellectia AI
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
IPO Tracker 2026: Cardio biotech Kardigan binds off $400M upsized IPO - BioSpace
Kardigan surges in Nasdaq debut after upsized $400 million IPO - marketscreener.com
3 Under-the-Radar Stocks to Buy and Hold for a Decade - The Motley Fool
Kailera Therapeutics, Inc. Common Stock (NASDAQ: KLRA) Stock Price, News & Analysis - Kalkine
This Stock Is Up 58% This Year. Is It too Late to Buy? - AOL.com
‘I worry deeply about bioterrorism’: Is Europe sufficiently prepared for another pandemic? - Yahoo! Finance Canada
Parabilis sets biotech IPO record with $670M raise - MSN
Parabilis Is Now the Largest VC-Backed Biotech IPO - Morningstar
Kailera (KLRA) CEO exercises stock options, now holds 38,094 shares - Stock Titan
Parabilis now the largest VC-backed biotech IPO - Yahoo Finance
Parabilis Breaks Kailera’s Short-Lived Biopharma IPO Record - Citeline News & Insights
Parabilis sets a record with a $670M biotech IPO - BioPharma Dive
Parabilis takes top spot, pricing largest biopharma IPO at $670M - BioWorld News
Parabilis Medicines raises $670M in upsized IPO - Axios
Parabilis targets $745 million in record-setting biotech IPO - The Pharma Letter
Cancer biotech Parabilis books record IPO, raising $670m - pharmaphorum
Parabilis ups planned IPO haul to record-setting $637M - Fierce Biotech
3 potential takeover targets in obesity - Pharma Voice
Kailera Therapeutics Launches Commercial Strategy Following $625 Million IPO - geneonline.com
New obesity drug ribupatide shows up to 12.1% weight loss in Phase 2 trial, advancing to global Phase 3. - Pluang
1.17%
2.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):